After APOLLO: Trevena Weighs Commercial Viability Of Opioid Oliceridine

A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.

More from Clinical Trials

More from R&D